In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...